ELVN Q4 2024 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$27M

Net Income

-$23M

EPS (Diluted)

$-0.46

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$326M

Total Liabilities

$16M

Stockholders' Equity

$310M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$27M	-$23M	-18.3%
Net Income	-$23M	-$19M	-19.7%